Bortezomib was found to cause decreased CIP2A expression in colon cancer, while its use in triple negative breast cancer resulted in reduced CIP2A mRNA expression and no variation in CIP2A degradation [96, 97]. Here, CIP2A is linked to colonic neoplasm.